Table 1 Characteristics of the included studies.

From: C-reactive protein and risk of breast cancer: A systematic review and meta-analysis

First author

Year

Study Year of recruitment

Country

Study design

Age, y

No. of Subjects/cases

Outcome assessment

Markers

CRP measurement methods

Il’yasova

2005

HABCS 1997-1998

USA

Cohort

73(70-79)

2438/33

Pathology reports

CRP

ELISA

Siemes

2006

Rotterdam 1989-1993

Netherlands

Cohort

69.6(9.2)

3790/184

Pathology reports

Hs-CRP

Rate Near-infrared Particle Immunoassay

Jacquotte

2007

NYUWHS

USA

Nested C-C

Not Given

248/85

Not Given

CRP

The Behring NA Latex Test

Zhang

2007

WHS 1992

USA

Cohort

54.5

274703/892

Medical records

CRP

Latex-enhanced Immunoturbidimetry

Heikkila

2009

BWHHS 1999-2001

British

Cohort

69.2

3274/48

Cancer registry

Hs-CRP

Ultrasensitive Nephelometry

Allin

2009

CCHS 1946-1978

Danish

Cohort

30-71

5561/207

Cancer registry

Hs-CRP

Turbidimetry or Nephelometry

Van Hemelrijck

2011

AMORIS 1985-1986

Sweden

Cohort

44.8(16.68)

54248/1241

Cancer registry

CRP

Turbidimetry

Gaudet

2013

CPS-II 1998-2001

USA

Nested C-C

50-74

594/297

Cancer registry

CRP

ELISA

Hong

2013

2008-2011

China

C-C

53.7(12.1)

1012/506

Medical records

CRP

ELISA

Prizment

2013

ARIC 1987-1989

USA

Cohort

45-64

35888/176

Cancer registry

Hs-CRP

Immunoturbidimetry

Ollberding

2013

Multiethnic 2001-2006

USA

Nested C-C

67.8(7.4)

1412/706

Cancer registry

CRP

Turbidimetry

Touvier

2013

SU.VI.MAX 1994-1995

France

Nested C-C

49.2(6.1)

654/218

Medical records

Hs-CRP

ELISA

Alokail

2013

Not Given

KSA

C-C

46.4(11.3)

109/56

Pathology reports

Hs-CRP

ELISA

Dossus

2014

E3N 1995-1999

France

Nested C-C

57.6(6.1)

1589/549

Pathology reports

CRP

Particle-enhanced Immunoturbidimetry

Wang

2014

Kailuan 2006-2011

China

C-C

49.2(11.3)

19437/88

Pathology reports

Hs-CRP

Nephelometry

  1. Abbreviations: HABCS, the Health Aging and Body Composition Study; NYUWHS, the New York University Women’s Health Study; WHS, the Women’s Health Study; BWHHS, the British Women’s Heart and Health Study; CCHS, the Copenhagen City Heart Study; AMORIS, the Apolipoprotein MOrtality RISk study; CPS-II, the American Cancer Society’s Cancer Prevention Study-II Nutrition Cohort; ARIC, the Atherosclerosis Risk in Communities Cohort Study; SU.VI.MAX, the Supplémentation en Vitamines et Minéraux Antioxydants Study; E3N, the E3N Cohort Study; CRP, C-reactive protein; Hs-CRP, High-sensitivity C-reactive protein; C-C, case-control; ELISA, enzyme linked immunosorbent assay.